Angiotensin-Converting Enzyme Inhibitors Potentiate Preconditioning Through Bradykinin B2Receptor Activation in Human Heart
Authors:
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activationJACC, 1996
- Preconditioning in isolated superfused human muscleJournal of Molecular and Cellular Cardiology, 1995
- ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionThe Lancet, 1995
- Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.Circulation, 1994
- Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.Circulation, 1994
- Reduction of Myocardial Infarct Size in Rabbits by RamiprilatJournal of Cardiovascular Pharmacology, 1993
- Ramiprilat increases bradykinin outflow from isolated hearts of ratBritish Journal of Pharmacology, 1993
- Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogsCardiovascular Research, 1993
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonistEuropean Journal of Pharmacology, 1990